Subscribe to professional news anytime
Based on pharmaceutical big data, AI pharmaceutical applies artificial intelligence technology to all aspects of pharmaceutical industry, which can improve the efficiency and quality of new drug research and development, and reduce the cost of research and development. Some analysts pointed out that with the continuous development of AI technology, its application in the pharmaceutical field will also increase.
In the face of the broad prospects of AI pharmaceuticals, at present, many technology companies have increased the layout of “AI+ medicine”, such as Microsoft, Nvidia and Google.
For example, Google DeepMind recently released a new generation of AlphaFold 3 model for predicting protein structure, which can help scientists more accurately target disease mechanisms, so as to develop more effective therapeutic drugs. DeepMind researchers say AlphaFold 3 is an artificial intelligence (AI) model that can predict the structure of biomolecules such as proteins, DNA, RNA and how they interact.
Specifically, the upgrade of AlphaFold 3 mainly adds the Diffusion Model to directly predict the 3D coordinates of atoms, and successfully extends the ability of AI to predict proteins to include DNA, RNA and other fields. It can make predictions about proteins, large biomolecules such as DNA and RNA, small molecules (also known as ligands), and even many drugs. Company officials said that in the next few years, there will be a large number of artificial intelligence-designed drugs into the clinic, bringing great benefits to human life and health.
The relevant person in charge of Nvidia also said that “AI+ medicine” will become the next “golden track”. It is reported that in 2023, Nvidia has invested in more than 10 AI pharmaceutical companies. Entering 2024, Nvidia’s tilt in AI pharmaceuticals is more obvious: at the 42nd jpmorgan Chase Healthcare Annual Meeting in early January, Nvidia announced that it had partnered with Amgen to establish an AI model platform called Freyja to accelerate and shorten the cycle of drug development; At the Nvidia GPU Technology Conference, which ended in March, there were more than 90 sessions related to life sciences/healthcare.
According to combing, many technology head companies are also making efforts in the field of drug research and development. For example, in 2023, Salesforce launched ProGen, a large model of protein-generating AI, Microsoft released a similar open source model EvoDiff, and Amazon released a protein folding tool for its AWS machine learning platform SageMaker.
At present, “AI+ medicine” is very hot and attracts attention from all parties. According to data, since 2021, there have been 281 global venture capital deals for AI drug development startups, with an investment of $7.7 billion. There are also statistics. In April 2024, 18 AI pharmaceutical companies raised more than 1.298 billion US dollars globally, of which 8 Chinese companies were funded. Xaira Therapeutics has raised more than $1 billion to become a hot spot, and a number of startups such as Diagonal Therapeutics and Somite.AI have also received significant investment, and AI is widely used in drug research and development, clinical trials and other fields.
However, some people also pointed out that the application of AI to drug research and development has great potential, but there is still a long way to go before it truly enters the pharmaceutical market. If some people say that the process of fully simulating drug development through AI large models has very high requirements for computing power, and sufficient training data is still a bottleneck. Others say that new foundational models like GPT rely on reinforcement learning, a learning process that mimics repeated training by humans to achieve goals, and rely more on high-quality, massive amounts of data.
Disclaimer: In no event does the information or opinions expressed herein constitute investment advice to anyone.
The article links: pharmaceutical https://www.zyzhan.com/news/detail/92347.html
About us
Changzhou Zhichao Medical Technology Co., LTD., founded in September 2011, is headquartered in Changzhou Hang Seng Science and Technology Industrial Park. Today, the company’s R&D center is engaged in the process research and development, production, optimization, custom synthesis and technology transfer of API or pharmaceutical intermediates, plant extracts, compounds from laboratory scale to commercial scaleup production, to meet the growing requirements of customers.
Zhichao Chemical attaches great importance to research and development and technology investment, and has established long-term strategic cooperation with domestic and foreign science academies, and has a branch in India. The team has developed and cooperated with related preparation projects, and difficult, small market volume, high value-added products, and in strict accordance with the international GMP standard management, products are exported to Europe, America, India, Southeast Asia, the Middle East and South America and other markets. At the same time, the company pays attention to the protection of intellectual property rights, constantly invents and innovates research and development of production processes, circumvent patent and intellectual property problems in the regulatory market, perfect impurity research, and provide customers with a full set of CMC or DMF registration documents.
